Preliminary analysis of 499 Ebola infected participants has sprung a surprise — the chances of survival may be as high as 90% if patients are treated with one of the two drugs – REGN-EB3 and mAb114 – soon after infection. The Ebola virus, which has had a free run so far, is all set to be … Continue reading Deadly Ebola virus on the brink of being tamed
Merck's Ebola vaccine, which underwent phase-3 trial during the 2014-2015 Ebola epidemic in west Africa, has shown 97.5% efficacy in preventing Ebola disease when used during the current epidemic in Congo. Due to vaccine shortage and increasing outbreaks, the dosage will be halved to match the dose tested in phase-3 trial. The efficacy of lower … Continue reading Merck’s unlicensed Ebola vaccine shows 97.5% efficacy in Congo
On July 17, the WHO finally declared Ebola virus disease outbreak in Congo a Public Health Emergency of International Concern. Since the beginning of the outbreak in August 2018, Ebola virus has killed nearly 1,700 people and made more than 2,500 people ill. Merck's vaccine has shown promise in protecting people. After holding back on … Continue reading WHO declares Ebola in Congo as public health emergency
Days after the WHO declared the end of the May 8 Ebola outbreak in the Democratic Republic of the Congo, a fresh outbreak was reported on August 1 in North Kivu. If Congo displayed its considerable experience and also promptness in its response to the May 8 outbreak, the WHO matched it with double-quick response. The investigational … Continue reading Can Congo again swiftly control Ebola spread, death?
The alacrity and eagerness shown by the research community to find a safe and efficacious vaccine against the deadly Ebola virus has borne fruit. The interim results of a Phase III clinical trial in Guinea using a novel virus vaccine (rVSV-ZEBOV) have shown 100 per cent efficacy after 10 days of vaccination. People who received … Continue reading Editorial: Victory over Ebola